Last updated on June 2018

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Amyotrophic Lateral Sclerosis
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • ALS patients within 12 months after clinical onset at the entry
  • Updated Awaji combined with El Escorial criteria: definite, probably or laboratory supported probable
  • Decline of ALSFRSR being 1 or 2 during observation period of 12 weeks
  • Japanese Clinical Severity Scale 1 or 2
  • Those who can visit the participating medical centers

Exclusion Criteria:

  • Those who have tracheostomy
  • Those who had NIPPV
  • %FVC<60%
  • Those who have Chronic Obstructive Pulmonary Disease (COPD)
  • Those who have symptoms and signs of B12 deficiency
  • Those who had edaravone less than 4 weeks prior to entry
  • Those who changed the schedule and dosing of riluzole
  • Those who have dementia
  • Those who have the possibility of pregnancy
  • Those who have serious respiratory or cardiac diseases
  • Those who have malignancies
  • Those who participated other clinical trials within 12 weeks
  • Those who have allergies to B12 and related compounds

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.